AC
BCRX icon

Apogem Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Apogem Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,219
Closed -$140K – 137
2022
Q2 		$140K Buy
+13,219
New +$136K 0.13% 143

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Apogem Capital's BCRX Position: Q3 2022 in Review

Apogem Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 13,219 shares — an estimated $140K sold.

Apogem Capital first reported a position in BCRX in Q2 2022 and held it in 1 quarter. The position peaked at $140K in Q2 2022. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Apogem Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Apogem Capital sold 13,219 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $140K.
  • Apogem Capital first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Apogem Capital's BioCryst Pharmaceuticals position peaked at $140K in Q2 2022.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Apogem Capital's 13F filing for Q3 2022, filed 14 Nov 2022.